Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension

Respiratory Medicine

Volumn 98, Issue 3, 2004, Pages 225-234

  Morales Blanhir, Jaime ^a   Santos, Salud ^a   De Jover, Lluis ^a   Sala, Ernest ^a,b   Paré, Carles ^a   Roca, Josep ^a   Rodriguez Roisin, Robert ^a   Barberà, Joan A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Nitric oxide; Prostacyclin; Pulmonary hypertension

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; TREATMENT INDICATION; TREATMENT OUTCOME; VASODILATATION;

EID: 1342288852     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.09.019     Document Type: Article

References (35)

1. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 1986;134:342-6.
2. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-8.
3. Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985;71:1191-6.
4. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
5. Rich S, editor. Executive Summary from the World Symposium on Primary Pulmonary Hypertension 1998. Co-sponsored by The World Health Organization, http://www.who.int/ncd/cvd/pph.html.
6. Gibbs JSR, Higenbottam T, Black C, et al. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;2001:i1-13.
7. Gaine S, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-25.
8. Galie N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;75:55A-62A.
9. Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 1991; 18:1323-7.
10. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140:1623-30.
11. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
12. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990;82:2018-26.
13. Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982;66: 334-8.
14. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-9.
15. Jolliet P, Bulpa P, Thorens JB, Ritz M, Chevrolet JC. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997;52:369-72.
16. Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998;32:1068-73.
17. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992;19:1060-4.
18. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-7.
19. Newman JH. Treatment of primary pulmonary hypertension - the next generation. N Engl J Med 2002;346:933-5.
20. Roger N, Barberà JA, Farre R, Cobos A, Roca J, Rodriguez-Roisin R. Effect of nitric oxide inhalation on respiratory system resistance in chronic obstructive pulmonary disease. Eur Respir J 1996;9:190-5.
21. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Raisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996;347:436-40.
22. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-8.
23. Ribas J, Angrill J, Barberà JA, et al. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J 1999;13:210-2.
24. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
25. Housset B, Snoey E, Chouaid C. Decision analysis. In: Derenne JP, Whitelaw WA, Similowski T, editors. Acute respiratory failure in chronic obstructive pulmonary disease. New York: Marcel Dekker; 1996. p. 847-66.
26. Dinh-Xuan AT, Higenbottam T, Clelland C, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive pulmonary disease. N Engl J Med 1991; 324:1539-47.
27. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83: 2038-47.
28. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
29. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
30. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000;35:176-82.
31. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001;22: 529-37.
32. Rich S, McLaughlin V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7.
33. Rich S, D'Alonzo GE, Dantzker DR, Levy PS. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. Am J Cardiol 1985;55: 159-63.
34. Rozkovec A, Stradling JR, Shepherd G, MacDermot J, Oakley CM, Dollery CT. Prediction of favourable responses to long term vasodilator treatment of pulmonary hypertension by short term administration of epoprostenol (prostacyclin) or nifedipine. Br Heart J 1988;59:696-705.
35. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.